Vivek Subbiah: Delighted to welcome Krish Patel as our new lymphoma leader SCRI
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Super delighted to welcome Dr. Krish Patel to Nashville as our new lymphoma leader Sarah Cannon Research Institute!
Dr. Patel is a renowned expert in hematologic malignancies and has over 100 + publications. It’s an exciting time for lymphoma drug development with unprecedented advances in the field Navneet Majhail, SCRI Oncology Partners.”
More posts featuring Vivek Subbiah on oncodaily.com
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023